{"hands_on_practices": [{"introduction": "The selection of a biologic mesh for hernia repair introduces a critical dynamic: the material is designed to degrade and be replaced by host tissue. This exercise delves into the fundamental kinetics of this process. By modeling the loss of tensile strength with a first-order differential equation, you will develop a quantitative understanding of the \"race\" between mesh degradation and tissue regeneration, a core concept in the use of any resorbable biomaterial. [@problem_id:5151797]", "problem": "A patient with a contaminated ventral hernia repair (Centers for Disease Control and Prevention (CDC) wound class III) is being considered for biologic mesh placement. In contaminated fields, biologic mesh tensile strength is often modeled to decline due to enzymatic degradation and remodeling according to first-order kinetics. Let the residual tensile strength of the mesh be $S(t)$ at time $t$, with $S(0)=S_{0}$, and assume the governing law is the first-order degradation differential equation $\\frac{dS}{dt}=-\\lambda S$, where $\\lambda$ is a constant degradation rate. \n\nStarting from this fundamental model, derive the general expression for the time $t_{\\alpha}$ at which the residual strength satisfies $S(t_{\\alpha})=\\alpha\\,S_{0}$ for a given fraction $\\alpha\\in(0,1)$. Then, for a biologic mesh with $\\lambda=0.1\\,\\text{month}^{-1}$, compute the specific time to $50\\%$ strength loss, that is $t_{1/2}$ corresponding to $\\alpha=\\frac{1}{2}$. Round your numerical answer to four significant figures and express the time in months.\n\nFinally, discuss qualitatively, based on the derived model and the computed $t_{1/2}$, the implications for using biologic mesh as a bridging material in contaminated fields where host collagen deposition and maturation to load-bearing capacity typically require multiple months.", "solution": "The problem statement has been critically evaluated and is determined to be valid. It is scientifically grounded, well-posed, and objective. The use of a first-order decay model for material degradation is a standard and appropriate simplification for the given biological context. I will now proceed with the solution.\n\nThe problem asks for three things: first, to derive a general expression for the time $t_{\\alpha}$ at which the residual tensile strength $S(t)$ of a biologic mesh reaches a fraction $\\alpha$ of its initial strength $S_0$; second, to compute this time for a $50\\%$ strength loss ($t_{1/2}$); and third, to discuss the clinical implications of this model.\n\nThe degradation of the mesh's tensile strength is governed by the first-order linear homogeneous ordinary differential equation:\n$$\n\\frac{dS}{dt} = -\\lambda S\n$$\nwith the initial condition $S(t=0) = S_0$. Here, $S(t)$ is the tensile strength at time $t$, $S_0$ is the initial tensile strength, and $\\lambda$ is the constant degradation rate.\n\nThis is a separable differential equation. We can rearrange the terms to separate the variables $S$ and $t$:\n$$\n\\frac{dS}{S} = -\\lambda \\, dt\n$$\nNext, we integrate both sides of the equation. We integrate the left side from the initial strength $S_0$ at time $t=0$ to the strength $S(t)$ at a general time $t$. Correspondingly, we integrate the right side from time $0$ to $t$:\n$$\n\\int_{S_0}^{S(t)} \\frac{1}{S'} \\, dS' = \\int_0^t -\\lambda \\, dt'\n$$\nThe evaluation of these definite integrals yields:\n$$\n[\\ln|S'|]_{S_0}^{S(t)} = [-\\lambda t']_0^t\n$$\nSince strength $S(t)$ is a physical quantity that must be positive, we can drop the absolute value.\n$$\n\\ln(S(t)) - \\ln(S_0) = -\\lambda t - (-\\lambda \\cdot 0)\n$$\nUsing the properties of logarithms, this simplifies to:\n$$\n\\ln\\left(\\frac{S(t)}{S_0}\\right) = -\\lambda t\n$$\nTo solve for $S(t)$, we exponentiate both sides of the equation:\n$$\n\\frac{S(t)}{S_0} = \\exp(-\\lambda t)\n$$\n$$\nS(t) = S_0 \\exp(-\\lambda t)\n$$\nThis equation describes the exponential decay of the mesh's tensile strength over time.\n\nNow, we derive the general expression for the time $t_{\\alpha}$ at which the residual strength is a fraction $\\alpha$ of the initial strength, i.e., $S(t_{\\alpha}) = \\alpha S_0$, where $\\alpha \\in (0, 1)$. We substitute this condition into our solution for $S(t)$:\n$$\n\\alpha S_0 = S_0 \\exp(-\\lambda t_{\\alpha})\n$$\nDividing both sides by $S_0$ (which is non-zero) gives:\n$$\n\\alpha = \\exp(-\\lambda t_{\\alpha})\n$$\nTo solve for $t_{\\alpha}$, we take the natural logarithm of both sides:\n$$\n\\ln(\\alpha) = \\ln(\\exp(-\\lambda t_{\\alpha}))\n$$\n$$\n\\ln(\\alpha) = -\\lambda t_{\\alpha}\n$$\nIsolating $t_{\\alpha}$ gives the general expression:\n$$\nt_{\\alpha} = -\\frac{\\ln(\\alpha)}{\\lambda}\n$$\nSince $\\alpha$ is a fraction between $0$ and $1$, its natural logarithm $\\ln(\\alpha)$ is negative, which ensures that $t_{\\alpha}$ is a positive value, as expected for time. The expression can also be written as $t_{\\alpha} = \\frac{\\ln(1/\\alpha)}{\\lambda}$.\n\nNext, we are asked to compute the specific time for a $50\\%$ strength loss, which is the half-life $t_{1/2}$. This corresponds to setting $\\alpha = 1/2 = 0.5$. The problem provides the degradation constant $\\lambda = 0.1 \\, \\text{month}^{-1}$.\nSubstituting these values into our general expression for $t_{\\alpha}$:\n$$\nt_{1/2} = -\\frac{\\ln(0.5)}{0.1} = \\frac{\\ln(1/0.5)}{0.1} = \\frac{\\ln(2)}{0.1}\n$$\nThe value of the natural logarithm of $2$ is approximately $\\ln(2) \\approx 0.693147...$. Therefore:\n$$\nt_{1/2} \\approx \\frac{0.693147}{0.1} \\, \\text{months} = 6.93147 \\, \\text{months}\n$$\nThe problem requires the answer to be rounded to four significant figures.\n$$\nt_{1/2} \\approx 6.931 \\, \\text{months}\n$$\n\nFinally, we discuss the qualitative implications. The model describes an exponential decay of mechanical strength. The calculated half-life, $t_{1/2} \\approx 6.931$ months, provides a quantitative measure of the durability of the biologic mesh in this simulated contaminated environment. This result means that the mesh is expected to lose half of its initial load-bearing capacity in approximately $7$ months.\n\nIn clinical practice, a biologic mesh used for hernia repair acts as a scaffold, providing mechanical support to the abdominal wall while the patient's own tissues remodel and integrate into the scaffold. The goal is for the host's own newly deposited collagen to mature and assume the load-bearing function before the mesh scaffold degrades to a point of mechanical failure. The problem states this maturation process requires \"multiple months.\"\n\nThe derived model and the computed half-life highlight a critical \"race\" between two competing processes: the degradation of the mesh and the regeneration of functional host tissue.\n1.  **Risk of Premature Failure**: If the mesh strength $S(t)$ drops below the minimum required to withstand physiological loads (e.g., intra-abdominal pressure from coughing or straining) before the host tissue is sufficiently strong, the repair will fail, leading to hernia recurrence. A half-life of about $7$ months indicates a substantial loss of strength within the typical healing window. For example, at $3$ months, the remaining strength would be $S(3) = S_0 \\exp(-0.1 \\times 3) = S_0 \\exp(-0.3) \\approx 0.74 S_0$, representing a $26\\%$ loss of strength.\n2.  **Bridging Function**: The term \"bridging material\" implies the mesh temporarily bridges a defect. The exponential decay kinetics mean the rate of strength loss is highest initially and slows over time. This continuous, predictable decline must be offset by a sufficiently rapid increase in the strength of the new tissue.\n3.  **Contaminated Fields**: The scenario of a CDC Class III wound is significant. Contaminated or infected environments are known to accelerate the degradation of biologic materials due to higher levels of enzymatic activity (e.g., from bacteria and inflammatory cells). Therefore, the value of $\\lambda=0.1 \\, \\text{month}^{-1}$ might even be an optimistic estimate. A higher $\\lambda$ would lead to a shorter half-life, increasing the risk of failure. This model demonstrates quantitatively how a more hostile biological environment (higher $\\lambda$) directly compromises the durability of the repair.\n\nIn conclusion, the first-order decay model, while a simplification, powerfully illustrates the fundamental challenge of using resorbable biologic meshes. The success of the surgical repair is critically dependent on the relationship between the mesh degradation rate ($\\lambda$) and the patient's tissue regeneration rate. The calculated half-life of approximately $7$ months quantifies the timeframe over which this biological handover must occur, underscoring the importance of selecting meshes with appropriate degradation profiles and optimizing patient conditions to promote rapid healing.", "answer": "$$\\boxed{6.931}$$", "id": "5151797"}, {"introduction": "While material properties are crucial, the patient's physiological state profoundly impacts surgical outcomes, especially in contaminated fields. This practice shifts the focus from the implant to the host, demonstrating how statistical models can translate patient-specific risk factors into actionable clinical insights. By applying a logistic regression model, you will quantify how optimizing a key metabolic parameter, HbA1c, can directly reduce the predicted probability of surgical site infection, informing both preoperative management and intraoperative decision-making. [@problem_id:5151866]", "problem": "A surgeon is planning a single-stage ventral hernia repair in a contaminated field and wants to quantify how preoperative optimization of Hemoglobin A1c (HbA1c) could change the predicted risk of Surgical Site Infection (SSI) to inform mesh selection (synthetic versus biologic) under contamination. Assume SSI risk is modeled by a validated logistic regression of the form\n$$\n\\text{logit}(p) \\equiv \\ln\\!\\left(\\frac{p}{1-p}\\right) = \\beta_{0} + \\beta_{1}\\,H + \\beta_{2}\\,I_{C} + \\beta_{3}\\,I_{D} + \\beta_{4}\\,I_{A},\n$$\nwhere $p$ is the probability of SSI, $H$ is HbA1c in percentage points, $I_{C}$ is an indicator for contaminated field, $I_{D}$ is an indicator for operative duration greater than $3$ hours, and $I_{A}$ is an indicator for timely and appropriate prophylactic antibiotics. Suppose the following well-tested parameter values have been obtained from prior studies in comparable abdominal wall reconstruction cohorts: $\\beta_{0} = -4.0$, $\\beta_{1} = 0.18$ per $1$ percentage point of HbA1c, $\\beta_{2} = 1.2$, $\\beta_{3} = 0.5$, and $\\beta_{4} = -0.4$.\n\nConsider a patient with $I_{C} = 1$, $I_{D} = 1$, and $I_{A} = 1$. Pre-optimization HbA1c is $H = 9$, and after a structured glycemic optimization program the HbA1c is reduced to $H = 7$. Using only the logistic model above and the definition of the logistic function $p = \\frac{1}{1 + \\exp(-\\text{logit}(p))}$, compute the absolute reduction in predicted SSI probability, defined as $\\Delta p \\equiv p(H{=}9) - p(H{=}7)$.\n\nRound your final answer to four significant figures and express it as a decimal (no percentage sign). In your own mind, consider how such a change in predicted risk might influence selection of synthetic versus biologic mesh in a contaminated field; however, for grading purposes, report only $\\Delta p$ as specified.", "solution": "The problem has been rigorously validated and is deemed valid. It is scientifically grounded in established principles of clinical biostatistics, specifically the use of logistic regression for risk prediction. The problem is well-posed, providing all necessary parameters and variables for a unique solution. The language is objective and the setup is complete and internally consistent.\n\nThe objective is to compute the absolute reduction in the probability of Surgical Site Infection (SSI), denoted as $\\Delta p$, when a patient's Hemoglobin A1c (HbA1c) is reduced from $H=9$ to $H=7$. The probability of SSI, $p$, is determined by a logistic regression model.\n\nThe logit of the probability $p$ is given by the linear model:\n$$\n\\text{logit}(p) = \\beta_{0} + \\beta_{1}\\,H + \\beta_{2}\\,I_{C} + \\beta_{3}\\,I_{D} + \\beta_{4}\\,I_{A}\n$$\nwhere $\\text{logit}(p)$ is defined as $\\ln\\left(\\frac{p}{1-p}\\right)$.\n\nThe given parameter values are:\n$\\beta_{0} = -4.0$\n$\\beta_{1} = 0.18$\n$\\beta_{2} = 1.2$\n$\\beta_{3} = 0.5$\n$\\beta_{4} = -0.4$\n\nThe specific conditions for the patient are:\n$I_{C} = 1$ (contaminated field)\n$I_{D} = 1$ (operative duration greater than $3$ hours)\n$I_{A} = 1$ (timely and appropriate prophylactic antibiotics)\n\nWe first calculate the logit value as a function of $H$ for this specific patient by substituting the indicator variables and parameter values into the model. Let $L(H) = \\text{logit}(p)$ for a given HbA1c, $H$.\n$$\nL(H) = \\beta_{0} + \\beta_{1}\\,H + \\beta_{2}\\,(1) + \\beta_{3}\\,(1) + \\beta_{4}\\,(1)\n$$\n$$\nL(H) = -4.0 + 0.18\\,H + 1.2 + 0.5 - 0.4\n$$\nCombining the constant terms, the expression for the logit simplifies to:\n$$\nL(H) = (-4.0 + 1.2 + 0.5 - 0.4) + 0.18\\,H\n$$\n$$\nL(H) = -2.7 + 0.18\\,H\n$$\nNext, we calculate the logit for the two HbA1c levels, $H_{initial}=9$ and $H_{final}=7$.\n\nFor the pre-optimization HbA1c, $H = 9$:\n$$\nL(9) = -2.7 + 0.18 \\times 9 = -2.7 + 1.62 = -1.08\n$$\nFor the post-optimization HbA1c, $H = 7$:\n$$\nL(7) = -2.7 + 0.18 \\times 7 = -2.7 + 1.26 = -1.44\n$$\nThe probability $p$ is recovered from its logit, $L$, using the logistic function:\n$$\np = \\frac{1}{1 + \\exp(-L)}\n$$\nWe now compute the predicted probabilities of SSI for each HbA1c level.\n\nFor $H=9$, the probability $p(H=9)$ is:\n$$\np(H=9) = \\frac{1}{1 + \\exp(-L(9))} = \\frac{1}{1 + \\exp(-(-1.08))} = \\frac{1}{1 + \\exp(1.08)}\n$$\nUsing a calculator, $\\exp(1.08) \\approx 2.944679$.\n$$\np(H=9) \\approx \\frac{1}{1 + 2.944679} = \\frac{1}{3.944679} \\approx 0.253506\n$$\nFor $H=7$, the probability $p(H=7)$ is:\n$$\np(H=7) = \\frac{1}{1 + \\exp(-L(7))} = \\frac{1}{1 + \\exp(-(-1.44))} = \\frac{1}{1 + \\exp(1.44)}\n$$\nUsing a calculator, $\\exp(1.44) \\approx 4.220696$.\n$$\np(H=7) \\approx \\frac{1}{1 + 4.220696} = \\frac{1}{5.220696} \\approx 0.191545\n$$\nThe absolute reduction in predicted SSI probability, $\\Delta p$, is the difference between these two probabilities:\n$$\n\\Delta p = p(H=9) - p(H=7)\n$$\n$$\n\\Delta p \\approx 0.253506 - 0.191545 = 0.061961\n$$\nThe problem requires the final answer to be rounded to four significant figures. The first four significant figures of $0.061961$ are $6$, $1$, $9$, and $6$. The fifth significant figure is $1$, which is less than $5$, so we do not round up.\n$$\n\\Delta p \\approx 0.06196\n$$\nThis value represents the absolute decrease in the risk of SSI achieved by reducing the patient's HbA1c from $9\\%$ to $7\\%$ under the specified operative conditions.", "answer": "$$\n\\boxed{0.06196}\n$$", "id": "5151866"}, {"introduction": "Modern surgical decision-making extends beyond immediate clinical success to encompass long-term outcomes and economic efficiency. This final practice integrates clinical probabilities and financial data into a comprehensive decision analysis framework. You will calculate the total expected cost of two competing mesh strategies by weighing the initial investment against the downstream costs of potential complications like infection, explantation, and recurrence. This exercise hones the ability to make evidence-based, value-conscious choices in complex clinical scenarios. [@problem_id:5151806]", "problem": "A tertiary-care surgical service is evaluating mesh selection for single-stage ventral hernia repair in a contaminated field (Centers for Disease Control and Prevention class III). Two strategies are considered: biologic mesh and permanent synthetic mesh. The evaluation horizon is two years with no discounting. From the hospital perspective, the total cost is defined as the sum of the index admission cost plus downstream costs due to Surgical Site Infection (SSI), mesh explantation, and hernia recurrence.\n\nAssume the following scientifically grounded structure and values, with events occurring at most once per patient within the horizon:\n- Index admission cost (inclusive of operative time, perioperative care, and mesh acquisition):\n  - Synthetic: $c_{\\text{init}}^{S} = \\$31{,}000$.\n  - Biologic: $c_{\\text{init}}^{B} = \\$45{,}000$.\n- Probability of SSI:\n  - Synthetic: $p_{\\text{SSI}}^{S} = 0.24$.\n  - Biologic: $p_{\\text{SSI}}^{B} = 0.21$.\n- Conditional probability of mesh explantation given SSI:\n  - Synthetic: $p_{E \\mid \\text{SSI}}^{S} = 0.35$.\n  - Biologic: $p_{E \\mid \\text{SSI}}^{B} = 0.10$.\n- If SSI occurs without explantation, an additional cost $c_{\\text{SSI}} = \\$12{,}000$ is incurred.\n- If explantation occurs (which only occurs if SSI occurs), the additional cost $c_{E} = \\$36{,}000$ is incurred; this cost includes the SSI management cost for that episode.\n- Two-year recurrence probabilities:\n  - If mesh is explanted: $p_{R \\mid E} = 0.55$.\n  - If mesh is retained (no explantation):\n    - Synthetic: $p_{R \\mid \\neg E}^{S} = 0.12$.\n    - Biologic: $p_{R \\mid \\neg E}^{B} = 0.22$.\n- Recurrence reoperation cost:\n  - If mesh was explanted: $c_{R \\mid E} = \\$30{,}000$.\n  - If mesh is retained: $c_{R \\mid \\neg E} = \\$22{,}000$.\n\nAssume that recurrence risk is conditionally independent of SSI status given whether the mesh was explanted. Let $p_{E}^{i} = p_{\\text{SSI}}^{i} \\cdot p_{E \\mid \\text{SSI}}^{i}$ for strategy $i \\in \\{S,B\\}$, and that there are no other costs or events.\n\nUsing first principles of expected value and conditional probability, compute the expected two-year total cost for each strategy and then select the strategy with the minimum expected cost. Report only the minimum expected cost. Express your final answer in thousands of United States dollars (kUSD) and round to four significant figures.", "solution": "The problem statement has been critically validated and is deemed to be a valid, well-posed, and scientifically grounded problem in decision analysis and applied probability. All necessary data, conditions, and assumptions are provided, and there are no internal contradictions or logical flaws. We may therefore proceed with the solution.\n\nThe objective is to compute the total expected two-year cost for two surgical strategies, synthetic mesh repair ($S$) and biologic mesh repair ($B$), for a ventral hernia in a contaminated field. The strategy with the minimum expected cost will be selected, and this minimum cost will be reported.\n\nLet $C^i$ be the random variable representing the total cost for a patient undergoing strategy $i$, where $i \\in \\{S, B\\}$. The total expected cost, $E[C^i]$, can be decomposed into the sum of the initial cost and the expected costs of downstream complications. The major complications are Surgical Site Infection (SSI), mesh explantation ($E$), and hernia recurrence ($R$).\n\nThe total expected cost is given by:\n$$E[C^i] = c_{\\text{init}}^i + E[\\text{Cost}_{\\text{SSI/E}}]^i + E[\\text{Cost}_{R}]^i$$\nwhere $c_{\\text{init}}^i$ is the initial cost, $E[\\text{Cost}_{\\text{SSI/E}}]^i$ is the expected cost from SSI and/or explantation, and $E[\\text{Cost}_{R}]^i$ is the expected cost from recurrence.\n\nFirst, we calculate the expected cost from SSI and explantation. A patient can have no SSI, SSI without explantation, or SSI with explantation. Explantation only occurs in the context of an SSI. The expected cost is the sum of the costs of each outcome multiplied by its probability.\nLet $p_{\\text{SSI}}^i$ be the probability of SSI for strategy $i$.\nLet $p_{E \\mid \\text{SSI}}^i$ be the conditional probability of explantation given an SSI.\nThe probability of explantation, $p_{E}^i$, is the probability of both SSI and explantation occurring:\n$$p_{E}^i = p(\\text{SSI} \\cap E)^i = p(E \\mid \\text{SSI})^i \\cdot p(\\text{SSI})^i = p_{E \\mid \\text{SSI}}^i \\cdot p_{\\text{SSI}}^i$$\nThe probability of SSI without explantation is $p(\\text{SSI} \\cap \\neg E)^i = p(\\text{SSI})^i - p(\\text{SSI} \\cap E)^i = p_{\\text{SSI}}^i - p_{E}^i$.\nThe cost of SSI without explantation is $c_{\\text{SSI}}$. The cost of explantation is $c_{E}$, which is inclusive of the SSI management cost.\nThe expected cost for SSI/Explantation is:\n$$E[\\text{Cost}_{\\text{SSI/E}}]^i = c_{\\text{SSI}} \\cdot (p_{\\text{SSI}}^i - p_{E}^i) + c_{E} \\cdot p_{E}^i$$\n\nNext, we calculate the expected cost from recurrence. The recurrence cost depends on whether the mesh was explanted. The recurrence probability is also conditional on the explantation status.\nLet $c_{R \\mid E}$ and $p_{R \\mid E}$ be the cost and probability of recurrence given explantation.\nLet $c_{R \\mid \\neg E}$ and $p_{R \\mid \\neg E}^i$ be the cost and probability of recurrence given no explantation for strategy $i$.\nThe expected cost of recurrence, by the law of total expectation, is:\n$$E[\\text{Cost}_{R}]^i = E[\\text{Cost}_R \\mid E] \\cdot p(E)^i + E[\\text{Cost}_R \\mid \\neg E] \\cdot p(\\neg E)^i$$\nThe expected costs within each conditional branch are $E[\\text{Cost}_R \\mid E] = c_{R \\mid E} \\cdot p_{R \\mid E}$ and $E[\\text{Cost}_R \\mid \\neg E] = c_{R \\mid \\neg E} \\cdot p_{R \\mid \\neg E}^i$.\nSince $p(E)^i = p_E^i$ and $p(\\neg E)^i = 1 - p_E^i$, this becomes:\n$$E[\\text{Cost}_{R}]^i = (c_{R \\mid E} \\cdot p_{R \\mid E}) \\cdot p_{E}^i + (c_{R \\mid \\neg E} \\cdot p_{R \\mid \\neg E}^i) \\cdot (1 - p_{E}^i)$$\n\nNow, we will compute the total expected cost for each strategy.\n\n**1. Synthetic Mesh Strategy (S)**\nThe given parameters are:\n$c_{\\text{init}}^{S} = \\$31{,}000$\n$p_{\\text{SSI}}^{S} = 0.24$\n$p_{E \\mid \\text{SSI}}^{S} = 0.35$\n$p_{R \\mid \\neg E}^{S} = 0.12$\nShared parameters:\n$c_{\\text{SSI}} = \\$12{,}000$\n$c_{E} = \\$36{,}000$\n$p_{R \\mid E} = 0.55$\n$c_{R \\mid E} = \\$30{,}000$\n$c_{R \\mid \\neg E} = \\$22{,}000$\n\nFirst, calculate the probability of explantation for the synthetic mesh:\n$$p_{E}^{S} = p_{\\text{SSI}}^{S} \\cdot p_{E \\mid \\text{SSI}}^{S} = 0.24 \\cdot 0.35 = 0.084$$\n\nNext, calculate the expected cost of SSI/Explantation:\n$$E[\\text{Cost}_{\\text{SSI/E}}]^{S} = c_{\\text{SSI}} \\cdot (p_{\\text{SSI}}^{S} - p_{E}^{S}) + c_{E} \\cdot p_{E}^{S}$$\n$$E[\\text{Cost}_{\\text{SSI/E}}]^{S} = \\$12{,}000 \\cdot (0.24 - 0.084) + \\$36{,}000 \\cdot 0.084$$\n$$E[\\text{Cost}_{\\text{SSI/E}}]^{S} = \\$12{,}000 \\cdot 0.156 + \\$3024 = \\$1872 + \\$3024 = \\$4896$$\n\nThen, calculate the expected cost of recurrence:\n$$E[\\text{Cost}_{R}]^{S} = (c_{R \\mid E} \\cdot p_{R \\mid E}) \\cdot p_{E}^{S} + (c_{R \\mid \\neg E} \\cdot p_{R \\mid \\neg E}^{S}) \\cdot (1 - p_{E}^{S})$$\n$$E[\\text{Cost}_{R}]^{S} = (\\$30{,}000 \\cdot 0.55) \\cdot 0.084 + (\\$22{,}000 \\cdot 0.12) \\cdot (1 - 0.084)$$\n$$E[\\text{Cost}_{R}]^{S} = (\\$16{,}500) \\cdot 0.084 + (\\$2640) \\cdot 0.916$$\n$$E[\\text{Cost}_{R}]^{S} = \\$1386 + \\$2418.24 = \\$3804.24$$\n\nFinally, the total expected cost for the synthetic mesh strategy is:\n$$E[C^S] = c_{\\text{init}}^S + E[\\text{Cost}_{\\text{SSI/E}}]^{S} + E[\\text{Cost}_{R}]^{S}$$\n$$E[C^S] = \\$31{,}000 + \\$4896 + \\$3804.24 = \\$39{,}700.24$$\n\n**2. Biologic Mesh Strategy (B)**\nThe given parameters are:\n$c_{\\text{init}}^{B} = \\$45{,}000$\n$p_{\\text{SSI}}^{B} = 0.21$\n$p_{E \\mid \\text{SSI}}^{B} = 0.10$\n$p_{R \\mid \\neg E}^{B} = 0.22$\n\nFirst, calculate the probability of explantation for the biologic mesh:\n$$p_{E}^{B} = p_{\\text{SSI}}^{B} \\cdot p_{E \\mid \\text{SSI}}^{B} = 0.21 \\cdot 0.10 = 0.021$$\n\nNext, calculate the expected cost of SSI/Explantation:\n$$E[\\text{Cost}_{\\text{SSI/E}}]^{B} = c_{\\text{SSI}} \\cdot (p_{\\text SSI}^{B} - p_{E}^{B}) + c_{E} \\cdot p_{E}^{B}$$\n$$E[\\text{Cost}_{\\text{SSI/E}}]^{B} = \\$12{,}000 \\cdot (0.21 - 0.021) + \\$36{,}000 \\cdot 0.021$$\n$$E[\\text{Cost}_{\\text{SSI/E}}]^{B} = \\$12{,}000 \\cdot 0.189 + \\$756 = \\$2268 + \\$756 = \\$3024$$\n\nThen, calculate the expected cost of recurrence:\n$$E[\\text{Cost}_{R}]^{B} = (c_{R \\mid E} \\cdot p_{R \\mid E}) \\cdot p_{E}^{B} + (c_{R \\mid \\neg E} \\cdot p_{R \\mid \\neg E}^{B}) \\cdot (1 - p_{E}^{B})$$\n$$E[\\text{Cost}_{R}]^{B} = (\\$30{,}000 \\cdot 0.55) \\cdot 0.021 + (\\$22{,}000 \\cdot 0.22) \\cdot (1 - 0.021)$$\n$$E[\\text{Cost}_{R}]^{B} = (\\$16{,}500) \\cdot 0.021 + (\\$4840) \\cdot 0.979$$\n$$E[\\text{Cost}_{R}]^{B} = \\$346.50 + \\$4737.36 = \\$5083.86$$\n\nFinally, the total expected cost for the biologic mesh strategy is:\n$$E[C^B] = c_{\\text{init}}^B + E[\\text{Cost}_{\\text{SSI/E}}]^{B} + E[\\text{Cost}_{R}]^{B}$$\n$$E[C^B] = \\$45{,}000 + \\$3024 + \\$5083.86 = \\$53{,}107.86$$\n\n**Comparison and Conclusion**\nComparing the total expected costs for the two strategies:\nExpected cost for Synthetic mesh: $E[C^S] = \\$39{,}700.24$\nExpected cost for Biologic mesh: $E[C^B] = \\$53{,}107.86$\n\nThe minimum expected cost is $\\min(\\$39{,}700.24, \\$53{,}107.86) = \\$39{,}700.24$, corresponding to the synthetic mesh strategy.\n\nThe problem requires the answer to be expressed in thousands of United States dollars (kUSD) and rounded to four significant figures.\nMinimum expected cost = $\\$39{,}700.24 = 39.70024 \\text{ kUSD}$.\nRounding to four significant figures gives $39.70$ kUSD.", "answer": "$$\\boxed{39.70}$$", "id": "5151806"}]}